Literature DB >> 20532626

Strategic lithotripsy using the Doli S EMSE 220 F-XP for the management of staghorn renal calculi.

Ioannis Heretis1, Charalampos Mamoulakis, Vaios Papadimitriou, Frank Sofras.   

Abstract

AIM: The presentation of our results using the Dornier lithotripter (Doli) S electromagnetic shockwave emitter (EMSE) 220 F-XP for the strategic management of staghorn renal calculi.
METHODS: Sixteen patients with renal staghorn stones of more than 35 mm in maximum length on plain X-rays were treated by shock wave lithotripsy (SWL) monotherapy with the Doli S EMSE 220 F-XP. Double-J ureteral stent was inserted to all prior to the first SWL treatment. Shock wave counts varied from 2,500 to 3,600 with a shock release frequency of 70-80 pulses per minute. The number of sessions varied from 2 to 6. The interval between the SWL sessions was around 1 month. Fragmentation rate of 20-25% of the stone load per session was considered a valid criterion for progressing to further SWL sessions.
RESULTS: Nine patients became stone free at the end of SWL sessions and two patients had renal stone fragments smaller than 4 mm, which were eliminated 6 months later. Two patients developed streinstrasse that was managed with ureteroscopy. Auxiliary SWL was also performed on three patients with residual ureteral calculi. The mean follow up period was 12 months. The remaining five patients underwent open surgery for incomplete stone fragmentation. No major complications developed during the follow up period. The predominant composition of stones available for analysis was struvite.
CONCLUSION: Doli S EMSE 220 F-XP can be a safe and effective treatment option for renal staghorn stones on an outpatient basis.

Entities:  

Mesh:

Year:  2010        PMID: 20532626     DOI: 10.1007/s11255-010-9765-0

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  16 in total

1.  Twenty years of single center experience in ESWL 1987-2007: an evaluation of 3079 patients.

Authors:  Geert G Tailly; Joost A Baert; K Robert Hente; Thomas O Tailly
Journal:  J Endourol       Date:  2008-10       Impact factor: 2.942

2.  Extracorporeal shock wave lithotripsy monotherapy for staghorn stones with the second generation lithotriptors.

Authors:  H Vandeursen; L Baert
Journal:  J Urol       Date:  1990-02       Impact factor: 7.450

3.  Monotherapy of staghorn renal calculi: a comparative study between percutaneous nephrolithotomy and extracorporeal shock wave lithotripsy.

Authors:  H N Winfield; R V Clayman; C G Chaussy; P J Weyman; G J Fuchs; A N Lupu
Journal:  J Urol       Date:  1988-05       Impact factor: 7.450

4.  Staghorn calculi of the kidney: classification and therapy.

Authors:  F Di Silverio; M Gallucci; G Alpi
Journal:  Br J Urol       Date:  1990-05

Review 5.  [Urinary tract infections and Urolithiasis].

Authors:  A Meissner; C Mamoulakis; N Laube
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

6.  Rapid communication: first clinical experience with Doli S 220F-XP extracorporeal lithotripter for urinary lithiasis.

Authors:  John Heretis; George Daskalopoulos; Odisseas Delibaltidis; Dimitrios Kalivianakis; Vaios Papadimitriou; Frank Sofras
Journal:  J Endourol       Date:  2006-07       Impact factor: 2.942

7.  Complete staghorn calculi: random prospective comparison between extracorporeal shock wave lithotripsy monotherapy and combined with percutaneous nephrostolithotomy.

Authors:  S Meretyk; O N Gofrit; O Gafni; D Pode; A Shapiro; A Verstandig; T Sasson; G Katz; E H Landau
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

8.  Staghorn calculi--long-term results of management.

Authors:  S Koga; Y Arakaki; M Matsuoka; C Ohyama
Journal:  Br J Urol       Date:  1991-08

9.  [Long-term clinical outcome of extracorporeal shock wave lithotripsy monotherapy for staghorn calculi].

Authors:  S Ashida; A Yamamoto; N Oka; S Masuda; K Yuasa; N Terao
Journal:  Hinyokika Kiyo       Date:  1998-08

10.  Dornier Lithotripter S 220 F EMSE: the first report of over 1000 treatments.

Authors:  Salvatore Micali; Maria C Sighinolfi; Marco Grande; Massimo Rivalta; Stefano De Stefani; Giampaolo Bianchi
Journal:  Urology       Date:  2009-10-07       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.